Novocure
NVCR
conference date: October 29, 2026, 5 AM Pacific Time
for quarter ending: September 30, 2026 (third quarter, Q3)

Forward-looking
statements
Overview: Strong revenue growth on a modest base. Note this is my first coverage of Novocure, so I am not as familiar with it as with the companies I already cover.
Basic data (GAAP):
Revenue: $193 million, up 5% sequentially from $184 million, and up 16% from $167 million year-earlier.
Net Income: negative $10.4 million, up sequentially from negative $15.7 million, and up from negative $37.3 million year-earlier.
EPS (Earnings per Share): negative $0.09, up sequentially from negative $0.13, and up from negative $0.33 year-earlier.
Guidance:
Increase full-year 2026 guidance for revenue range: $736 to $743 million. Adjusted EBITDA range: $24 million to $34 million.
Conference Highlights:
Frank Leonard, CEO, said "Novocure's strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launching in new markets, resulting in a record number of active patients on our therapies. We achieved record-high quarterly net revenue and are well-positioned to achieve the commercial, clinical and financial goals we set out in January. Based on the results from this quarter, we have raised our financial guidance for 2026 and will continue to build on the strong progress we have made on our path to profitability." Record number of patients in therapy.
We believe many more patients can benefit from Optune Gio. Has seen slowing in Pax launch in the U.S.
Revenue by nation: U.S. $111.9 million; Germany $24.9 million; France $18.7 million; Japan $14.5 million. Other $18.8 million. $4.4 millin was from a one-time benefit due to increased approval rates in the U.S. and Germany.
Revenue by type: Optune Lua $8.2 million. Optune Pax $3.7 million. I presume the rest is Optune Gio, the first approved device.
Current patients by type: Gio 4,729; Lua 255; Pax 238.
In October 2026 Japan approved Optune Pax for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.
In October 2026 Novocure entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of TTFields therapy with chemotherapy and VS-7375, an investigational oral, potent and selective KRAS G12D inhibitor, for locally advanced pancreatic cancer.
In Q4 2026 Novocure expects the FDA premarket appproval for TTFields for brain metastates from NSCLC. Also anticipates completing enrollment in Phase 3 KEYNOTE D58 clinical trial in newly diagnosed glioblastoma.
Optune Mia (sp?) is now under review at the FDA.
EBITDA was negative $1.76 million, adjusted EBITSA $15.7 million.
Cash, equivalents, and short-term investments ended the quarter at $464 million. Credit facility debt $196 million.
Cost of revenues was $44.5 million. R&D $58.1 million. Marketing $53.3 million. Admin $43.6 million. Total expenses $155 million. Operating loss $6 million. Financial expense $1.7 million. Income tax $2.6 million.
Q&A:
Pax trends? Strip volumes? Challenges in the U.S. launch. Patients come in asking for daraxonrasib (Rasonque). Insurance approval process is lengthy. Many patients get skin irritation. Practices are overwhelmed. We do see continued physician interest, clinical value is stong in first line. We think the situation will settle down in future quarters.
EBITDA trends? Committed to path to profitability. Caution will be fluctuations quarter to quarter; Q3 was particularly high for some specific reasons. Getting ready for launches.
Lua and Pax reimbursement in Japan? Plan a national symposium in January for Lua. Pax reimbursement should come in early 2027. Working on pricing. GBM incidence is low in Japan, but the new indications have higher rates of incidence.
We had a lot of unsolicited inquiries at ESMO for Optune Pax.
NCCN guidelines, we are looking for inclusion in pancreatic cancer. If approved would trigger additional payer interest.
Q4 decrease in revenue guidance? Very high Q3, had $4.4 million one-time revenue.
Verastem collaboration? Could be best in class. Locally advanced, first line pancreatic cancer. Hoping the combination will have better results than Pax alone. About 25 patients.
OpenIcon
Analyst Conference Summaries Main Page
|